Resumen de acción EX9 Exelixis, Inc. es una empresa oncológica dedicada al descubrimiento, desarrollo y comercialización de nuevos medicamentos contra cánceres difíciles de tratar en Estados Unidos. Saber más
Recompensas Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de Exelixis, Inc. Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del Exelixis Precios históricos de las acciones Precio actual de la acción US$31.55 Máximo en las últimas 52 semanas US$36.13 Mínimo de 52 semanas US$18.26 Beta 0.53 Cambio en 1 mes -3.31% Variación en 3 meses -5.17% Cambio de 1 año 52.86% Variación en 3 años 88.58% Variación en 5 años 72.67% Variación desde la OPV 62.63%
Noticias y actualizaciones recientes
Exelixis, Inc. Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025 Jan 26
Exelixis, Inc. Announces Results from Subgroup Analysis of Phase 3 Cabinet Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented At ASCO GI 2025 Jan 25 Exelixis, Inc. to Report Q4, 2024 Results on Feb 11, 2025
Exelixis Inc. Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (Cabometyx®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors Jan 09
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors Nov 27
Independent Director recently sold €940k worth of stock Nov 07 Ver más actualizaciones
Exelixis, Inc. Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025 Jan 26
Exelixis, Inc. Announces Results from Subgroup Analysis of Phase 3 Cabinet Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented At ASCO GI 2025 Jan 25 Exelixis, Inc. to Report Q4, 2024 Results on Feb 11, 2025
Exelixis Inc. Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (Cabometyx®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors Jan 09
Exelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors Nov 27
Independent Director recently sold €940k worth of stock Nov 07
Investor sentiment improves as stock rises 23% Nov 07 Exelixis, Inc. Reports Impairment of Long-Lived Assets for the Third Quarter Ended September 30, 2024
Exelixis, Inc. to Report Q3, 2024 Results on Oct 29, 2024 Oct 16 Exelixis, Inc Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine
Independent Director recently sold €831k worth of stock Aug 14
Exelixis, Inc. Announces Initiation of Phase 1 Clinical Trial Evaluating XB010 in Patients with Advanced Solid Tumors Aug 08
Second quarter 2024 earnings released: EPS: US$0.78 (vs US$0.25 in 2Q 2023) Aug 07 Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $500 million worth of its shares.
Exelixis, Inc. Announces U.S. Food and Drug Administration Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors Aug 06
Exelixis, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Jul 24
Independent Director recently sold €531k worth of stock May 24 Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA May 22
First quarter 2024 earnings released: EPS: US$0.12 (vs US$0.12 in 1Q 2023) May 01
Exelixis, Inc. Reaffirms Earnings Guidance for the Year 2024 May 01
Exelixis, Inc., Annual General Meeting, May 30, 2024 Apr 20
Exelixis, Inc. to Report Q1, 2024 Results on Apr 30, 2024 Apr 17
Executive Vice President of Commercial recently sold €932k worth of stock Mar 03
Full year 2023 earnings released: EPS: US$0.65 (vs US$0.57 in FY 2022) Feb 07
Exelixis, Inc. Provides Earnings Guidance for the for Fiscal Year 2024 Feb 07
Exelixis, Inc. Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024 Jan 25 Bristol Myers Squibb and Exelixis, Inc. Announce Four-Year Follow-Up Results from the CheckMate -9ER Trial Evaluating Opdivo (cabozantinib) Jan 24
Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares. Jan 09 Exelixis, Inc. (NasdaqGS:EXEL) announces an Equity Buyback for $450 million worth of its shares.
Exelixis Announces Initiation of the Stellar-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer Dec 04
Exelixis, Inc. Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023 Nov 11
Third quarter 2023 earnings released: EPS: US$0.003 (vs US$0.23 in 3Q 2022) Nov 02
Exelixis, Inc. Announces Detailed Results from Phase 3 Cabinet Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023 Oct 23
Exelixis, Inc. to Report Q3, 2023 Results on Nov 01, 2023 Oct 19
Exelixis, Inc. Announces Positive Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Pancreatic and Extra-Pancreatic Neuroendocrine Tumors Aug 25 Exelixis, Inc. Announces Vicki L. Goodman Concludes Her Service as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023 Aug 04
Exelixis, Inc. to Report Q2, 2023 Results on Aug 01, 2023 Jul 21
Exelixis, Inc. Elects Dave Johnson to its Board of Directors Jun 01
First quarter 2023 earnings released: EPS: US$0.12 (vs US$0.21 in 1Q 2022) May 10
Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2023 May 10
Exelixis Announces Departure of Lance Willsey, M.D. From Board of Directors May 08 Bristol-Myers Squibb Company and Exelixis, Inc. Announces Opdivo in Combination with Cabometyx Shows Durable Survival with over Three Years of Follow-Up in the Checkmate -9Er Trial in First-Line Advanced Renal Cell Carcinoma Feb 15
Exelixis, Inc. and Sairopa B.V. Announces US FDA Clears Investigational New Drug Application for ADU-1805 in Patients with Advanced Solid Tumors Feb 14
Full year 2022 earnings released: EPS: US$0.57 (vs US$0.73 in FY 2021) Feb 08
Exelixis, Inc. Provides Revenue Guidance for Fiscal Year 2023 Feb 08
Exelixis, Inc. to Report Q4, 2022 Results on Feb 07, 2023 Jan 10
Exelixis, Inc. Provides Revenue Guidance for Full Year 2023 Jan 09 Exelixis, Inc. Announces Initiation of the STELLAR-304 Phase 3 Pivotal Trial Evaluating Zanzalintinib in Patients with Advanced Non-Clear Cell Kidney Cancer Dec 23
Exelixis, Inc. Announces Board Appointments Dec 17
Exelixis, Inc. Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy Dec 10
Exelixis, Inc. Announces Initial Dose-Escalation Results from the First-In-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022 Dec 09
Insufficient new directors Nov 16
Third quarter 2022 earnings released: EPS: US$0.23 (vs US$0.12 in 3Q 2021) Nov 03
Exelixis, Inc. Provides Revenue Guidance for 2022 Nov 02
Exelixis, Inc. Announces Promising Initial Dose-Escalation Results from the First-In-Human Phase 1 JEWEL-101 Trial Evaluating XB002 in Patients with Advanced Solid Tumors at ENA 2022 Oct 27
Exelixis, Inc. to Report Q3, 2022 Results on Nov 01, 2022 Oct 19
Exelixis, Inc. Announces Dose-Escalation Results from the Phase 1 STELLAR-001 Trial Evaluating XL092 Alone and in Combination with an Immune Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ESMO 2022 Sep 11
Exelixis, Inc. Announces Detailed Results from Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer at ESMO 2022 Sep 08
Second quarter 2022 earnings released: EPS: US$0.22 (vs US$0.31 in 2Q 2021) Aug 11
Exelixis, Inc. Maintains Earnings Guidance for the Fiscal Year 2022 Aug 10
Exelixis, Inc. to Report Q2, 2022 Results on Aug 09, 2022 Jul 28
Exelixis, Inc. Announces COSMIC-313 Met Its Primary Endpoint Jul 12
Investor sentiment improved over the past week Jun 25
Exelixis Announces Initiation of the STELLAR-303 Phase 3 Pivotal Trial Evaluating XL092 in Patients with Metastatic Colorectal Cancer Jun 22
Executive Vice President of Commercial recently sold €320k worth of stock Jun 04
Exelixis, Inc. Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients May 27
Exelixis, Inc. Provides Earnings Guidance for the Fiscal Year 2022 May 12
First quarter 2022 earnings released: EPS: US$0.21 (vs US$0.005 in 1Q 2021) May 11
Insufficient new directors Apr 27 Exelixis, Inc. Announces Initiation of First-In-Human Phase 1 Trial Evaluating XL114 Monotherapy in Patients with Non-Hodgkin’s Lymphoma
Exelixis, Inc. Announces Charles Cohen to Retire from Board of Directors Apr 14
Co-Founder & Independent Chairman recently sold €1.5m worth of stock Mar 02
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Feb 18
Exelixis, Inc. Provides Earnings Guidance for the Year 2022 Feb 18
Bristol Myers Squibb and Exelixis, Inc. Announces Two-Year Follow-Up Results from Analyses of the Phase 3 CheckMate -9ER Trial Feb 15
Exelixis, Inc. Provides Sales Guidance for the Year 2022 Feb 11
Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022 Jan 19
Exelixis, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2021; Revenue Guidance for the Full Year 2022 Jan 10 Rentabilidad de los accionistas EX9 DE Biotechs Mercado DE 7D -2.3% 2.3% 0.5% 1Y 52.9% -2.6% 15.3%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: EX9 superó a la industria German Biotechs, que obtuvo un rendimiento del -2.6% el año pasado.
Rentabilidad vs. Mercado: EX9 superó al mercado German, que obtuvo un rendimiento del 15.3% el año pasado.
Volatilidad de los precios Is EX9's price volatile compared to industry and market? EX9 volatility EX9 Average Weekly Movement n/a Biotechs Industry Average Movement 6.3% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Precio estable de las acciones: El precio de las acciones de EX9 ha sido volátil durante los últimos 3 meses en comparación con el mercado German.
Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de EX9 en el último año.
Acerca de la empresa Exelixis, Inc. es una empresa oncológica dedicada al descubrimiento, desarrollo y comercialización de nuevos medicamentos contra cánceres difíciles de tratar en Estados Unidos. La empresa ofrece CABOMETYX comprimidos para el tratamiento de pacientes con carcinoma avanzado de células renales que recibieron terapia antiangiogénica previa; y COMETRIQ cápsulas para el tratamiento del cáncer medular de tiroides progresivo y metastásico. CABOMETYX y COMETRIQ se derivan del cabozantinib, un inhibidor de múltiples tirosina quinasas, incluidos los receptores MET, AXL, RET y VEGF.
Mostrar más Resumen de fundamentos de Exelixis, Inc. ¿Cómo se comparan los beneficios e ingresos de Exelixis con su capitalización de mercado? Estadísticas fundamentales de EX9 Capitalización bursátil €9.22b Beneficios(TTM ) €449.51m Ingresos (TTM ) €2.00b
20.6x Ratio precio-beneficio (PE)
4.6x Ratio precio-ventas (PS) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de EX9 Ingresos US$2.08b Coste de los ingresos US$78.00m Beneficio bruto US$2.00b Otros gastos US$1.54b Beneficios US$466.92m
Últimos beneficios comunicados
Sep 30, 2024
Próxima fecha de beneficios
Feb 11, 2025
Beneficios por acción (BPA) 1.64 Margen bruto 96.25% Margen de beneficio neto 22.43% Ratio deuda/patrimonio 0%
¿Cómo se ha desempeñado EX9 a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2025/02/06 07:33 Precio de las acciones al final del día 2025/02/05 00:00 Beneficios 2024/09/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github .
Fuentes analistas Exelixis, Inc. está cubierta por 42 analistas. 20 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución Ishan Majumdar Baptista Research Peter Lawson Barclays Etzer Darout BMO Capital Markets Equity Research
Mostrar 39 más analistas 
